Document is current
Any future updates will be listed below
-
Authors
Elewaut, Anais https://orcid.org/0009-0009-4064-7320
Estivill, Guillem https://orcid.org/0000-0002-8088-3098
Bayerl, Felix https://orcid.org/0000-0002-4737-1808
Castillon, Leticia
Novatchkova, Maria
Pottendorfer, Elisabeth
Hoffmann-Haas, Lisa
Schönlein, Martin https://orcid.org/0000-0002-1010-0975
Nguyen, Trung Viet https://orcid.org/0009-0000-1574-9610
Lauss, Martin
Andreatta, Francesco https://orcid.org/0000-0003-2749-9115
Vulin, Milica https://orcid.org/0000-0002-7686-5102
Krecioch, Izabela
Bayerl, Jonas https://orcid.org/0000-0001-6270-2823
Pedde, Anna-Marie
Fabre, Naomi
Holstein, Felix https://orcid.org/0000-0002-3729-9857
Cronin, Shona M.
Rieser, Sarah
Laniti, Denarda Dangaj https://orcid.org/0000-0002-5659-6427
Barras, David https://orcid.org/0000-0001-8985-4704
Coukos, George https://orcid.org/0000-0001-8813-7367
Quek, Camelia https://orcid.org/0000-0002-1244-961X
Bai, Xinyu
Muñoz i Ordoño, Miquel https://orcid.org/0009-0003-4391-6393
Wiesner, Thomas
Zuber, Johannes https://orcid.org/0000-0001-8810-6835
Jönsson, Göran https://orcid.org/0000-0001-6865-0147
Böttcher, Jan P. https://orcid.org/0000-0002-8163-8107
Vanharanta, Sakari https://orcid.org/0000-0001-5619-7963
Obenauf, Anna C. https://orcid.org/0000-0002-9556-5914
- License Information
-
More Information
Article History
Received: 1 September 2023
Accepted: 21 October 2024
First Online: 27 November 2024
Competing interests
: The laboratories of A.C.O. and J.Z. received research support and funding from Boehringer Ingelheim. J.Z. is a founder and scientific advisor of Quantro Therapeutics. G.C. has received grants from Celgene, Boehringer-Ingelheim, Roche, BMS, Iovance Therapeutics, and Kite Pharma. The institution that G.C. is affiliated with has received fees for his participation on an advisory board or for presentation at a company-sponsored symposium from Genentech, Roche, BMS, AstraZeneca, NextCure, Geneos Tx, and Sanofi/Avensis. G.C. has patents in the domain of antibodies and vaccines targeting the tumour vasculature, as well as technologies related to T cell expansion and engineering for T cell therapy. G.C. has received royalties from the University of Pennsylvania regarding CAR T cell technology. G.C. is a named inventor on patent applications filed by the Ludwig Institute for Cancer Research pertaining to the subject matter disclosed herein. D.D.L. has received a grant from Hoffmann-La Roche. All other authors declare no competing interests.
